Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 16:05 ET
|
Vera Therapeutics
BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Present at Upcoming Investor Conferences
November 22, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
November 17, 2022 07:30 ET
|
Vera Therapeutics
Dr. Barratt will discuss disease burden and pathogenesis of IgAN, a common cause of kidney failure and a high unmet medical need globally Event held Monday, November 28, 2022 at 2pm ET BRISBANE,...
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 09, 2022 07:30 ET
|
Vera Therapeutics
Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy topline data planned to be presented in early Q1 2023Initiated pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis...
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting
November 05, 2022 16:50 ET
|
Vera Therapeutics
New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN)Atacicept is the first therapeutic to show reduction in all of the...
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting
October 17, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Present at Upcoming Conferences in September 2022
September 07, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 10, 2022 07:30 ET
|
Vera Therapeutics
Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1 2023Presented positive 12-week interim analysis of Phase...
Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
August 04, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
July 06, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...